# Study of HRS-5041 in Patients With Metastatic Castration Resistant Prostate Cancer (mCRPC)

> **NCT05942001** · PHASE1 · RECRUITING · sponsor: **Jiangsu HengRui Medicine Co., Ltd.** · enrollment: 100 (estimated)

## Conditions studied

- Advanced Prostate Cancer

## Interventions

- **DRUG:** HRS-5041

## Key facts

- **NCT ID:** NCT05942001
- **Lead sponsor:** Jiangsu HengRui Medicine Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2023-08-03
- **Primary completion:** 2025-08-31
- **Final completion:** 2025-08-31
- **Target enrollment:** 100 (ESTIMATED)
- **Last updated:** 2025-02-19


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05942001

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05942001, "Study of HRS-5041 in Patients With Metastatic Castration Resistant Prostate Cancer (mCRPC)". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT05942001. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*